Isomerase
 

Important announcement from Isomerase partner ISR:
 
ISR Holding and the biotechnology company TCER AB have begun work on developing a vaccine against the Coronavirus. Data from animal studies are expected to be ready during the second quarter of 2020. The goal is for the vaccine to start testing in humans during the last quarter of this year. The vaccine is based on TCER AB's platform technology for the production of proteins and ISR's drug pipeline with immunostimulating immunolides.
 
“The coronavirus affects the lungs far down in the bronchioles . To prevent the virus from becoming infected, we must advance our immunological protection barriers to vaccination, a principle that we and TCER develop together. Our hope is that the vaccine will begin to be tested in humans during the fourth quarter of 2020, ”comments Ola Winqvist, CEO ISR.

ISR and TCER are now developing a new principle for vaccines against the Coronavirus to optimize the immunological protection against the virus.
“Our platform for the production of proteins for clinical use is fast and flexible. We see it as natural to help quickly produce Coronavirus proteins that are incorporated into a new vaccination strategy ”, comments Samuel Svensson, CEO, TCER AB.
 
These immunolides were licensed from Isomerase in 2017 (https://isomerase.co.uk/index.php/more-info/news/43-immune-system-regulation-holding-ab-and-isomerase-therapeutics-ltd-sign-acquisition-and-license-agreement-based-on-the-next-generation-of-immune-regulatory-drug-candidates) and Isomerase has been supporting their development on behalf of ISR since then.
 
If you would like any more information on the work that Isomerase and ISR and their other partners are doing to help treat covid-19, please get in touch via our contacts page.

About Isomerase
Our team is uniquely placed to assist partners with all aspects of discovery and development of microbial natural products, such as leading edge synthetic biology, advanced strain improvement of microorganisms, genome sequence analysis, protein and peptide expression and isolation, small scale fermentation and process development, DSP, compound isolation, analytical development and synthetic chemistry. In addition, as required, Isomerase also manages all other aspects necessary for a commercially successful programme on behalf of partners, such as compound management and shipping, scaled manufacture and tailored drug discovery screening cascades.
We offer these capabilities underpinned by an extensive portfolio of technology IP, and the combined experience of a core technical and leadership team with a substantive track record of successful drug discovery and development collaborations with pharma and biotech companies.
We have supported numerous companies with a wide variety of microbial product and small molecule fermentation and synthetic chemistry projects, helping advance early stage concepts into valuable development programmes, and then continuing to support their progress to market with process improvement and scaled manufacture.
To find out more, visit: www.isomerase.co.uk